Laboratories

Print

Clinical Chemotherapy

Overview

Our laboratory studies the resistant mechanisms and prediction of therapeutic effects of molecular target therapy by means of biochemistry, molecular biology, and cell imaging. We also carry out the collaborative investigation with the pathological laboratory and the treatment departments. Several national hospitals and public cancer centers have the laboratory which designated 'Laboratory of Clinical Chemotherapy' or 'Department of Clinical Chemotherapy' Among these laboratory, our division consists of physicians who hold the additional post in the 'clinical oncology' or 'hematology oncology' of the Cacner Institute Hospital as well as basic researchers, and promote collaborative investigation. As is known, in Japan, although the basic studies were superior, the application to a subsequent clinical development and a study to lead to new medicine concretely were not necessarily studied in enough excellent environment. Therefore we spend a power on the clinical data-managing, the processing, isolation, and preservation of specimens, and conduct the mediation with fundamental researches and the clinic in order to make good use of the kindness from patients.

Projects

  1. The significance of circulating tumor cells and circulating endothelial cells in solid tumor
  2. The clinical trial-based translational researches including breast cancer, bone-metastatic cancer and caner of unknown primary
  3. Prediction of therapy effect of molecular target drugs and mutation analysis of the target molecules
  4. sThe application of fluorescent imaging to the search of a biomarkers predicting the therapeutic effects
  5. The application of fluorescent imaging to the diagnosis of hematopoietic tumors (fluorescence 3D blood atlas)
  6. The functional analysis of novel protein RNF137 involved in antitumor effect of imatinib
  7. The biomarker study in the gastrointestinal carcinoma chemotherapy
  8. Discovery of novel biomarker and molecular target therapy, based on the carcinogenic mechanism in the urologic cancer

Original Web SiteNew Window

Publications

Publications

Matsusaka, S., Chin, K., Ogura, M., Suenaga, M., Shinozaki, E., Mishima, Y., Terui, Y., Mizunuma, N., Hatake, K.
Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer.
Cancer Sci, 101, 1067-1071 (2010)
Mishima, Y., Sugimura, N., Matsumoto-Mishima, Y., Terui, Y., Takeuchi, K., Asai, S., Ennishi, D., Asai, H., Yokoyama, M., Kojima, K., Hatake, K.
An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Clin Cancer Res, 15, 3624-3632 (2009)
Terui, Y., Mishima, Y., Sugimura, N., Kojima, K., Sakurai, T., Kuniyoshi, R., Taniyama, A., Yokoyama, M., Sakajiri, S., Takeuchi, K., Watanabe, C., Takahashi, S., Ito, Y., Hatake, K.
Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Clin Cancer Res, 15, 2523-2530 (2009)

Contact

Kiyohiko HatakeiChiefj
3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
TelF81-3-3570-0508 FaxF81-3-3570-0465
E-mailFkhatake@jfcr.or.jp

Return to Top Page